"A Phase 3, Global, Randomized, Double-Blind Trial of Tazemetostat in Combination with Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma"
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Epizyme, Inc
Start Date
August 6, 2020
End Date
April 1, 2022
Administered By
Duke Cancer Institute
Awarded By
Epizyme, Inc
Start Date
August 6, 2020
End Date
April 1, 2022